Ruben Bellotti

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Endoplasmic Reticulum Stress

Dendritic Cells

Immune Response

Papillary Thyroid

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)
Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)
Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)
Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)
Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)
Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner-Velano, Cornelia Lass-Flörl, Manuel Maglione
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.) 29 (12) (2022)